Tvardi Therapeutics Inc

Tvardi Therapeutics operates with a high liquidity position, as evidenced by $49.24 million in cash and equivalents, which significantly exceeds its total liabilities of $60.90 million, resulting in a current ratio of 4.59. The company's price-to-book ratio of 3.2 and price-to-tangible-book ratio of 3.2 suggest that the market is valuing the company at a premium to its book value, despite its negative net income of $20.02 million.

The company's profitability metrics are weak, with a return on equity of -1.73 and a return on assets of -0.28, both significantly below the industry median for biotechnology firms. The operating loss of $18.80 million and net loss of $20.02 million indicate that the company is not yet generating positive returns for shareholders.

Tvardi Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure at this time. The company's growth trajectory is uncertain, as the available data does not include forward-looking revenue guidance or historical growth rates.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 3.42 indicates a relatively high level of leverage, but the company's cash position provides a buffer against short-term liquidity pressures. No dilution risks were identified in the available data, and the number of shares outstanding has not changed between basic and diluted shares.

Recent events include analyst price targets ranging from $3.00 to $15.00, with a mean of $8.17 and a median of $8.00. Analysts have issued a total of 2 strong-buy, 2 buy, and 3 hold recommendations, indicating a generally positive but cautious outlook.

Tvardi Therapeutics Inc (TVRD.O) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker. As of March 31, 2026, investor ID 931 acquired a position of 128 shares, valued at approximately $0.0004 million. This acquisition represents a weight of roughly 0.000000195% of the company's equity, signaling initial institutional or significant individual interest in the biopharmaceutical firm. This development is particularly relevant given the company's current market profile. Tvardi Therapeutics is currently followed by only two analysts and has no index memberships, suggesting limited mainstream financial coverage. The entry of a new holder, even with a micro-cap position, may indicate early-stage accumulation or strategic positioning ahead of potential catalysts, though the absolute size of the stake remains negligible in terms of voting power or market influence. The company's governance structure is currently streamlined, with only one officer listed in the available data. With 14 top holders identified in the broader shareholder registry, the addition of investor ID 931 contributes to a modestly diversified ownership base. However, the lack of prior basis for delta computation means this is the first recorded movement of this nature, preventing any trend analysis regarding holder behavior over time. For investors, this signal serves as a baseline marker for future monitoring. While the financial impact of this specific transaction is immaterial to the company's overall valuation, it establishes a reference point for tracking institutional interest. As Tvardi Therapeutics continues to develop its pipeline, changes in holder composition will be key indicators of market sentiment, especially in the absence of broader analyst consensus or index inclusion. [doc:tvrd.o-ha-financials] [doc:tvrd.o-ha-estimates] [doc:tvrd.o-ha-esg]

Operating income +29,8% YoY; Net income +42,8% YoY.

• ▍Operating income +29,8% YoY
• ▍Net income +42,8% YoY
• ▍Free cash flow +42,8% YoY

Operating income −4,6% YoY; Net income −0,2% YoY.

• ▍Operating income −4,6% YoY
• ▍Net income −0,2% YoY
• ▍Free cash flow +1,0% YoY

Operating income +52,8% YoY; Net income +120,8% YoY.

• ▍Operating income +52,8% YoY
• ▍Net income +120,8% YoY
• ▍Free cash flow +120,9% YoY

Revenue $2.6M; Operating income -$2.4M.

• ▍Revenue $2.6M
• ▍Operating income -$2.4M
• ▍Net margin -191.0%

Operating income -$10.8M.

• ▍Operating income -$10.8M

Operating income -$5.7M.

• ▍Operating income -$5.7M

Revenue $991.0k; Operating income -$18.8M.

• ▍Revenue $991.0k
• ▍Operating income -$18.8M
• ▍Net margin -2019.8%

Operating income +4,8% YoY; Net income +38,0% YoY.

• ▍Operating income +4,8% YoY
• ▍Net income +38,0% YoY
• ▍Free cash flow +38,2% YoY

Operating income +76,9% YoY; Net income +75,2% YoY.

• ▍Operating income +76,9% YoY
• ▍Net income +75,2% YoY
• ▍Free cash flow +75,7% YoY

Revenue $21.0M, −49,9% YoY; Operating income −38,8% YoY.

• ▍Revenue $21.0M, −49,9% YoY
• ▍Operating income −38,8% YoY
• ▍Net income −38,6% YoY
• ▍Free cash flow −41,5% YoY
• ▍Net margin -565.2%

Revenue $41.9M, +81,8% YoY; Operating income +1,7% YoY.

• ▍Revenue $41.9M, +81,8% YoY
• ▍Operating income +1,7% YoY
• ▍Net income +3,4% YoY
• ▍Free cash flow +3,4% YoY
• ▍Net margin -204.2%

Revenue $23.0M; Operating income -$89.1M.

• ▍Revenue $23.0M
• ▍Operating income -$89.1M
• ▍Net margin -384.1%